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Introduction 
MUCH interest currently exists in the possibility of 
pharmacologically modifying the disease process 
in osteoarthritis (OA). A number of pharmacologic 
agents have been shown to reduce proteolytic 
cartilage breakdown and/or stimulate matrix 
repair in animal models of OA. Such agents have 
been called 'chondroprotective' drugs, although it 
has been suggested recently that the preferable 
term is DMOAD (disease-modifying OA drug) [1]. 
Purported DMOADs range from empirical com- 
pounds, e.g., tissue extracts [2], to site-specific 
collagenase inhibitors designed, by structural 
analysis, to fit precisely into the catalytic site of 
the enzyme [3]. Excellent reviews of the subject by 
Howell et al. [4] and by Di Pasquale [5] have been 
published recently. Agents that have been reported 
to exhibit a DMOAD effect in animal models of 
OA include tribenoside, tamoxifen, diacerhein, 
chloroquin, hyaluronic acid, glucocorticoids, 
tranexamic acid, heparinoids, nonsteroidal anti- 
inflammatory drugs (NSAIDs), and doxycycline. 
The evidence that progression of articular 
cartilage damage in animal models of OA may be 
modified pharmacologically heightens the need for 
better methods to detect early cartilage damage 
and assess progressive cartilage changes in 
humans with OA. When considering uidelines for 
testing DMOADs, committees of the International 
League against Rheumatism, Osteoarthritis Re- 
search Society and World Health Organization 
have recently emphasized that assessment of 
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disease modification in OA requires measurement 
of changes in the anatomy of the joint [1], rather 
than merely in concentrations of biochemical or 
immunochemical 'markers' of joint damage or 
repair in serum, synovial fluid or urine [6]. 
Chondroscopy [7] and ultrasonography [8] hold 
potential for serial assessment of patients with OA. 
Although the resolution of magnetic resonance 
imaging (MRI) has steadily improved, surface coils 
and careful technique are required for detection of 
focal cartilage thinning and surface defects [9], 
and the ability of diagnostic MRI to provide the 
precise measurements of cartilage thickness 
needed to evaluate changes in this parameter over 
time in a large joint, such as the knee [10], has not 
yet been sufficiently validated; and the cost of MRI 
remains relatively high. The above committees 
considered that none of these alternative ap- 
proaches has been sufficiently validated to permit 
a recommendation that it be used as an outcome 
measure at this time and that 'joint radiography, if 
standardized with respect o technique and views 
obtained, is the best technique available today for 
use in a large clinical trial of a DMOAD' [1]. In 
support of that view, double-contrast arthrography 
has recently confirmed the accuracy and precision 
of radiographic measurement of joint space width 
(JSW) for assessing cartilage thickness in the OA 
knee [11]. 
Prospects for identifying a DMOAD study 
population at risk for rapid progression 
Research on the effects of DMOADs in humans 
has been hampered by uncertainty regarding the 
appropriate patient population for clinical trials of 
such agents. Clinical trials of DMOADs may be 
conducted in subjects with established OA, or 
alternatively, in subjects in whom the target joint 
is radiographically normal but at high risk for the 
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rapid development of OA. The choice of a 
high-risk, but radiographically normal, knee as a 
target joint may be influenced also by the 
reasonable xpectation that a DMOAD effect will 
be more readily demonstrated in an OA joint in 
which pathologic hanges are mild than in a joint 
in which they are much more advanced [6, 7]. 
Although that contention is hypothetical, it is 
supported by the results of studies of doxycycline 
therapy in a canine cruciate-deficiency model of 
OA: when treatment was delayed until cartilage 
lesions were well-established, cartilage damage 
progressed more slowly than in the untreated OA 
controls--but damage was clearly present; when 
treatment commenced before gross or histologic 
cartilage changes had developed, the severity of 
OA was strikingly reduced, and in some cases, the 
cruciate-deficient knee remained grossly normal, 
whereas untreated controls showed extensive 
end-stage changes of OA [12, 13]. 
Recent epidemiologic data from Chingford, 
England, strongly suggest hat a select population 
of obese, middle-aged women with radiographic 
evidence of unilateral knee OA may afford an 
opportunity to observe (and prevent) the rapid 
onset of OA in a joint at high risk for OA--the 
radiographically normal contralateral knee [14]. 
Forty-seven per cent of this group (15 of 32) 
progressed from unilateral to bilateral disease 
within 2 years. It should be noted, however, that 
OA progression in the Chingford Study was 
determined chiefly on the basis of osteophyte 
growth; only two of the 15 subjects, whose OA was 
considered to progress, showed narrowing of JSW 
in addition to osteophyte growth. However, 
radiographs in this study were obtained with knees 
in full extension, and strict attention was not paid 
to standardizing the position of the knee on 
repeated examinations. (This probably accounts 
for the fact that osteophytosis seen in one subject 
at baseline was not apparent in the repeat 
radiograph.) Furthermore, OA progression in the 
Chingford Study was adjudicated without quanti- 
tative measurement of JSW [14]. The degree to 
which the development of OA in the high-risk 
contralateral knee of this select group was 
accompanied by joint space narrowing (JSN) is, 
therefore, unknown. 
With respect o the power of a DMOAD trial, the 
advantage of rapid OA progression in a high-risk 
knee which is radiographically normal at baseline 
may be multiplied by increased precision with 
which JSW can be measured in such a joint, in 
comparison with a knee with established bony 
changes of OA. Posit ioning--and reproducibil ity 
of reposit ioning--of the knee of a patient with 
severe OA, with constraining osteophytes and 
capsular fibrosis, may be more difficult than that 
of a knee in a subject with less-advanced changes. 
Furthermore, osteophytosis, ubchondral sclerosis 
and cartilage calcification can obscure the mar- 
gins of the joint space and make measurements of
JSW less reproducible than in the radiographically 
normal knee. This advantage is theoretical, 
however; the degree to which the severity of OA 
impairs the reproducibil ity of JSW measurements 
is unknown. 
Key  var iab les  in  knee  rad iography  
Obtaining a satisfactory plain radiograph of the 
knee is not a trivial matter. As discussed recently 
by Buckland-Wright [15, 16], several steps in 
the production of the conventional plain knee 
radiograph make quality control difficult: for 
example, the technician performing the examin- 
ation may have de~eloped his or her own 
preference for positioning of patients, especially 
when faced with someone who is markedly obese 
or who otherwise has difficulty standing or 
walking. Idiosyncratic variation in technique can 
lead to unintended variation in the degree of knee 
flexion, misalignment of the X-ray beam, and 
magnification of the radiographic image of the 
joint. 
DEGREE OF KNEE FLEXION 
Since publication of the classic monograph by 
Ahlback [17] and the supporting paper by Leach 
et al. [18], the standard knee radiograph has 
typically been obtained with the patient standing 
and the joint fully extended. However, in patients 
with advanced OA, radiographs obtained with the 
knee fully extended tend to overestimate the 
amount of cartilage remaining on the articular 
surface. Exaggeration of the magnitude and 
variability of JSW in radiographs taken with the 
knee in the extended position (see below) is caused 
by the femur 'riding up' on cartilage at the anterior 
margin of the tibia [19]. In contrast, the semiflexed 
position more closely approximates the normal 
anatomic standing position of the tibiofemoral 
joint than the fully-extended view [20, 21]. Arthro- 
scopic findings confirm that the semiflexed view is 
more likely than a fulLextension view to display 
the region of the tibiofemoral compartment in 
which cartilage damage in OA is most prevalent 
[19]. 
Various specific degrees of flexion have been 
suggested as providing increased sensitivity for 
demonstrating cartilage loss in the standing knee 
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radiograph. For example, Resnick and Vint [22] 
described six patients in whom the standing 
anteroposterior (AP) view underestimated the 
degree of joint space loss evident on a 'tunnel' 
view, i.e., knee flexed to 60 ° or 70 °. Messieh et al. 
[19] compared the standing AP view with a 
posteroanterior view with 30 ° flexion and found 10 
patients who had normal joint space on the 
fully-extended view, but marked narrowing on the 
flexion view. Alternatively, Rosenberg et al. [23] 
have suggested that 45 ° of knee flexion is superior 
to either 10 ° or 30 ° of flexion for detecting JSN. 
While the optimal degree of flexion for knee 
radiographs may be debated, the need for 
standardization with respect to flexion was 
demonstrated recently by Ravaud et al. [24], who 
found 10-12.5% variation in estimates of 
tibiofemoral JSW from repeated radiographs of 
normal knees in which knee flexion was manipu- 
lated by as little as 5 ° . 
Buckland-Wright as recently reported [25] that 
the precision (i.e., reproducibility of repeated 
measures) of JSW can be improved markedly by 
use of fluoroscopy to standardize knee flexion. 
Unlike the techniques in the above studies, which 
required fixed degrees of flexion, Buckland- 
Wright's protocol specifies the identification by 
fluoroscopy of the degree of flexion for each subject 
that results in superimposition f the anterior and 
posterior lips of the tibial plateau. This degree of 
flexion results in the positioning of the plateau in 
a plane parallel to the floor. This radiographic 
technique is further standardized by having the 
subject, while still under fluoroscopy, rotate the 
foot (with the heel fixed) until the tibial spines 
are centered below the femoral notch. The 
outline of the foot is traced on a film jacket 
to facilitate repositioning of the knee during 
repeat examinat ions  [25]. Deviations in foot 
rotation of as little as 15 ° may result in significant 
variation of estimates of JSW in repeated 
radiographs [24]. 
X-RAY BEAM ALIGNMENT 
The position of the central ray of the X-ray beam 
relative to the center of the joint, i.e., the joint 
space, is another important variable. The X-ray 
beam is tangent to the plane of the joint at a single 
point on the radiograph. All other points in the 
image are distorted because the X-ray beam 
diverges in a cone-shaped manner around the 
central tangent ray. Therefore, a change in 
the angle of the beam will result in distortion of 
the relationships of the articular margins on the 
radiograph projection. This distortion increases 
with increasing angulation (i.e., increasing dis- 
tance from the central ray). The degree of 
misalignment of the beam necessary to alter 
results is not large; Fife et al. [26] found a 17% 
decrease in JSW when the X-ray beam was 
displaced by 1 cm below its original alignment 
centered at the mid-point of the patella. Ravaud 
et al. [24] also detected significant reductions of 
JSW in repeated measurements of JSW in which 
the angle of inclination varied 5 ° from a line 
parallel to the joint space. 
RADIOGRAPHIC MAGNIFICATION 
Although radiographic magnification is not 
generally taken into account, the distance between 
the center of a joint and the X-ray film will affect 
the degree of magnification of the radiographic 
image. The distance between the center of the joint 
and the X-ray film can be large, and is influenced 
by factors such as obesity (common in subjects 
with knee OA) and restriction of joint movement 
because of pain, osteophytosis or soft tissue 
contracture. In an assessment of standard radio- 
graphs of the knee obtained in the standing 
extended view, Buckland-Wright et al. [25] found 
magnification of JSW ranging from 9-35% relative 
to a fixed magnification marker. Buckland- 
Wright's protocol for standardized knee radiogra- 
phy requires that a magnification marker (i.e., a 
5ram ball encased in plexiglass or another 
semi-radiolucent material) be affixed with tape to 
the skin overlying the head of the fibula [25]. Any 
measurement of JSW from that image can be 
corrected for the degree of magnification apparent 
in the image of the marker. 
Reproduc ib i l i ty  o f  quant i ta t ive  rad iograph ic  
measurements  
The validity of measurements of the radio- 
graphic features of OA is dependent not only upon 
image quality, but also upon the reproducibility of
the mensural procedure [27, 28]. Some investi- 
gators have reported estimates of JSW without 
describing their methods in detail [29, 30]. Others 
have used a ruler [31, 32] or calipers [1, 33] and/or 
a magnifying lens with a fitted graticule [34]. 
Although regarded as more precise than semi- 
quantitative scoring systems [35], such as the 
Kellgren and Lawrence scale [36], the reproducibil- 
ity of these quantitative methods (i.e., the degree 
to which repeated examinations of the same joint 
by the same observer, or by different observers, 
yield the same estimate of JSW) is subject to 
observer error. 
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The reproducibi l ity (or precision) of a mensural 
procedure for JSW measurement can be expressed 
as the standard deviation (S.D.) of repeated 
measurements of JSW within the same joint(s)--  
also referred to as the standard error of measure- 
ment (SEre). To standardize the scale of precision 
estimates, the reproducibil ity of repeated measure- 
ments of the same individuals is frequently 
quantified as a coefficient of variation (CV), the 
ratio of the S.D. to the mean of repeated 
measurements. Lack of attention to standardiz- 
ation of the technique in routine clinical knee 
radiography can result in a CV as high as 20% for 
repeated manual measurements (i.e., with a ruler) 
of JSW made directly on fully-extended, AP views 
of the same subjects [37]. In contrast, Lequesne 
[1, 33] has described a highly-standardized method 
of manual JSW measurement in which the points 
of a pair of calipers are used to measure the 
interbone distance on a radiograph. The points are 
then used to prick a sheet of paper on which the 
distance between the pinpricks is measured with a 
10x magnifying lens fitted with a 10 mm graticule 
with 0.1 mm divisions. The intra-observer CV for 
repeated measures with this technique was 3.8% 
[25]. 
The magnitude of human error that may be 
present even in highly-standardized manual 
measurement of JSW was i l lustrated recently in a 
study of 25 patients with knee OA and 10 normal 
controls [25], in which four repeated JSW 
measurements, made manually with a calipers on 
conventional plain radiographs of the knee (i.e., 
fully-extended, AP view, no correction for magnifi- 
cation) were compared with JSW measurements 
made with specialized edge-detection computer 
software [38] in digitized radiographic images of 
the same subjects, obtained during four examin- 
ations with standardized positioning in semiflex- 
ion and correction for image magnification [25]. 
For the 10 radiographically normal knees, the 
variabil ity (i.e., S.D.) of repeated manual measure- 
ments from conventional extended view radio- 
graphs [median S.D.=0.31mm, 95% confidence 
interval (CI)=0.14-0.48 mm], in relation to mean 
JSW, yielded a CV of 6.4%. Computerized 
measurement alone did not reduce the error 
variation in JSW measurement caused by lack of 
standardization f the position of the knee (median 
S.D. = 0.29 mm, CV = 6.2%), while addition of mag- 
nification correction resulted in only modest 
further reduction of the S.D. of repeated measures 
(median S.D. = 0.21 mm, CV = 5.4%). However, when 
the automated, magnification-corrected measure- 
ment system was applied to JSW measurement on 
radiographs of normal knees ~n the 
position, the S.D. was decreased by nearly half 
(median S.D. = 0.11 mm, CV = 3.2%, P < 0.01). 
In the above analysis, application of automated 
JSW measurement and magnification correction to 
images of 25 OA knees in optimal semiflexed 
position significantly (P< 0.01) reduced error 
variance across four repeated measurements 
(median S.D.=0.19 mm, CV=5.5%) relative to 
manual measurement in conventional radiographs 
(median S.D. =0.30 mm, CV= 6.4%). Although the 
improvement was not as great as that observed in 
examinations of radiographically normal knees, 
automated, magnification-corrected measurement 
in studies of the semifiexed OA knee reduced error 
variation by about one third, compared with 
manual measurement of JSW without these 
refinements. Even greater improvement in the 
reproducibil ity of automated, magnification-cor- 
rected JSW measures was reported with the use of 
high-definition 5 x macroradiographic images (me- 
dian S.D. = 0.06, 95% CI = 0:04-0.08, CV = 1.6%) [25]. 
However, microfocal radiography of joints is not 
widely available in clinical radiology departments 
in the United States, and therefore, could not be 
readily employed today in a mult icenter clinical 
trial of a DMOAD in this country. 
Quantitat ive radiographic studies of  knee OA 
Because disease modification in OA should 
preserve articular cartilage and slow the rate of 
JSN, two questions are key to the design of a 
clinical trial of a DMOAD in which the primary 
outcome is based on serial measures of JSW: what 
is the mean and variabil ity of JSW in the target 
population? At what overall rate does JSW narrow 
over time? Here, too, interpretation of published 
estimates of these population parameters must be 
tempered by knowledge of the subjects tudied and 
the radiographic and mensural procedures em- 
ployed. 
JO INT  SPACE WIDTH 
Table I summarizes published estimates of 
minimum JSW (mean ± S.D.) in the medial 
tibiofemoral compartment in normal subjects and 
patients with knee OA [31, 33, 39 41]. Although 
variabil ity in knee positioning confounds efforts to 
compare the results of these studies, the largest 
estimates of JSW were reported when the 
radiograph was obtained with the knee in extended 
position. Indeed, the mean JSW in OA knees in 
extended position estimated by Kirwan et al. [39] 
(4.45 mm) was larger than that found by Buckland- 
Wright [40] for normal knees in the standardized, 
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semiflexed position (4.06mm). Relatively-large 
mean values for OA knees in the extended position 
also have been reported by others (3.56 mm by 
Lequesne [33], 4.89-5.06 mm by MaziSres [31]). 
Even more striking than variance in the mean 
JSW--and more relevant o sample size require- 
ments in DMOAD tr ia ls--the s.D. of JSW 
measurements of OA knees in the extended view 
(2.01ram) found by Kirwan et al. [39] was 
substantially larger than those reported by 
Buckland-Wright for the semiflexed view of either 
normal or OA knees (Table I). In the latter study, 
the S.D. for computerized measures of tibiofemoral 
JSW in the normal semifiexed knee was 0.79 mm, 
while that for OA knees with a JSW greater 
than 3.0ram was 0.50mm, and for knees with 
JSW of 1.5-3.0 ram, S.D. was 0.58 mm [40]. Similarly, 
S.D.S of 0.74-0.81mm were reported for 29 OA 
knees of participants in the placebo group of 
a clinical trial of NSAID, in which baseline 
JSW in all patients was greater than 2 mm (Table I) 
[411. 
In summary, conventional radiography and 
manual measurement of JSW appear to offer 
larger, more variable estimates of JSW than does 
the combination of computerized measurement of
JSW in semiflexed views of the knees. The 
implication of the data presented in Table I is that, 
as designers of DMOAD trials decide upon the 
magnitude of the between-group difference in JSW 
to be detected, that difference will be a smaller 
proportion of within-group variabil ity for conven- 
tionally derived outcome measures than for 
highly-standardized and computerized measure- 
ments. In theory, therefore, conventional radiogra- 
phy and manual measurement of JSW will reduce 
the power of a DMOAD trial. 
RATE OF  JSN 
The magnitude of the difference in JSW between 
treatment and placebo groups to be detected in a 
DMOAD trial will be predicated on assumptions 
regarding the overall rate of JSN expected in the 
placebo group and the degree to which JSN will be 
slowed in the treatment group by the DMOAD. An 
assumption about he overall inear rate of JSN for 
the placebo group cannot be derived easily. The 
course of cartilage loss in individuals is likely to 
be marked by intermittent intervals of progression, 
of varying duration. It also is reasonable to expect 
biological variabil ity among subjects in the rate of 
JSN. JSN in the general elderly population or in 
people with untreated, early knee OA (who are 
likely to be identified by community-based recruit- 
ing efforts) may be slower than that in a clinic 
population of OA patients with established 
disease. Therefore, designers of DMOAD trials will 
need to consider both the overall rate and 
variabil ity of JSN in potential populations. 
Table iI summarizes published estimates of the 
rate of medial tibiofemoral JSN in patients with 
knee OA. Unfortunately for comparative purposes, 
previous studies of JSN in OA knees have varied 
markedly from one another in many important 
respects: sample size, source of the sample (clinic 
vs community), severity of OA, heterogeneity of
patient characteristics that may relate to OA 
progression (e.g., age, sex, obesity), radiographic 
technique, mensural procedures and durat ion of 
observation. Because of these differences in 
methodology, estimates of the annual rate of JSN 
in OA knees in the seven studies listed in Table II 
range from 0.06mm/year [42] to 0.60mm/year 
[39, 43]--10-fold var iat ion-- far  too large to be 
Table i 
Published estimates of medial tibiofemoral joint space width (JSW) at the narrowest point 
Study Knee position/ Number Mean JSW, mm 
(first author) method of measurement of knees OA severity (iS.D. when reported) 
Kirwan [39] Extended/ruler 150 
Lequesne [33]  Extended/calipers 22 
Mazigres [31] Extended/ruler 167 
Buckland-Wright [40] 
Buckland-Wright [41] 
Semiflexed/computer* 
Semiflexed/computer* 
14 
90 19 
15 
29 
Variable 4.54 + 2.01 
Variable 3.56 
Variable right: 4.89 
left: 5.06 
Normals 4.06 _+ 0.79 
Minimalt 3.77 ± 0.50 
Moderate]- 2.04 ± 0.58 
Markedt 1.64 ± 0.79 
JSW°> 2mm 3.39 ± 0.74 (baseline) 
3.36 i 0.77 (6 months) 
3.35 ± 0.73 (12 months) 
3.27 ± 0.81 (18 months) 
*Computerized measurement of digitized 5xmaeroradiographic images. ]-Minimal OA sever- 
ity = JSW > 3 ram; moderate OA = JSW 1.5-3.0 mm; marked OA = JSW < 1.5 mm. NA = not available. 
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Table II 
Published studies of medial tibiofemoral joint space narrowing (JSN) in knees with bony changes of OA 
Number Average Observed JSN Annual rate 
Study of follow-up over follow-up period, of JSN Point of 
(First author) knees (years) mean _+ S.D. (mm) (mm/year) measurement 
Ravaud [43] 55 1 Reader 1 Reader 2 
0.42 _+ 1.1 0.47 + 0.9 
0.45 __+ 1.2 0.60 ± 1.1 
0.26 + 1.2 0.37 + 1.1 
0.4~0.47 
0.450.60 
0.2~0.37 
Mazi6res [31] 167 1 Left knee: 0.26 ± 1.6 0.26 
Right knee: 0.13 _+ 1.3 0.13 
Buckland- 17 1.5 0.275 _+ 0.2685 0.183 
Wright [41] 
Kirwan [39] 150 3 1.85 _+ 1.88 0.60 
Lethbridge- 36t 4 Women: 0.24 _+ 0.56* 0.06 
~ejku [42] Men: 0.36 _+ 0.68* 0.09 
Lequesne [33] 22 3.9 1.01 ± 0.78* 0.26 
24 7.7 1.69 _+ 1.62" 0.22 
Neuhauser [44] 40t 8.1 0.81 _+ 1.05" 0.10 
Narrowest 
Midpoint 
10 mm from 
medial extremity 
Not reported 
Not reported 
Narrowest 
Narrowest 
Not reported 
Midpoint 
Midpoint 
Narrowest 
*Cumulative measurements were not reported. Observed JSN is extrapolated from reported annual averages of JSN. 
tA subset of a population-based sample; all other studies reflect JSN in clinic-based samples of OA patients. 
$Signal knees: the symptomatic OA knee of each subjects for which JSW was nearest to ,(but still greater than) 2 mm 
at baseline [personal communication from the authors]. 
conclusive for the planning of a placebo-controlled 
DMOAD trial without consideration of the patient 
characteristics and methodologic features that 
may, in part, be responsible for such variability. It 
is noteworthy, however, that both Mazi~res [31] 
and Lequesne [33], in studies that differed 
markedly with respect o sample size and duration, 
obtained estimates of 0.26mm/year in patients 
with established knee OA. In fact, 0.26 ram/year is 
the median of the estimates of annual rate of JSN 
presented in Table II. 
Table II lends support o the hypothesis that sub- 
jects with knee OA recruited from the community 
will have a slower overall rate of OA progression 
than those from clinic populations. Estimates of 
JSN in the population-based Baltimore Longitudi- 
nal Study of Aging [42] and the Framingham Study 
[44] yielded rates at the lower end of the spectrum 
(0.06-0.10mm/year). The remaining studies in 
Table II, all of which used clinical samples, had 
consistently higher values for annual JSN (i.e., 
generally more than 0.20 ram/year). 
Additional support of this hypothesis can be 
found in the study by Buckland-Wright et al. [41], 
who measured, on average, reasonably rapid 
progression (0.183 mm/year) in the index or 'signal' 
knees (i.e., the symptomatic knee with JSW nearest 
to, but still greater than 2 mm at baseline) of 17 OA 
patients in the placebo group of a clinical trial of 
an NSAID (J. C. Buckland-Wright, personal 
communication). However, in separate analyses of 
all 34 knees of the participants in the placebo 
group, the mean rate of narrowing was approxi- 
mately 0.08 ram/year among knees with greater 
than 50% of JSW at baseline, but about 
0.25 mm/year in knees with less than 50% of JSW 
at baseline [41]. Although sample size limitations 
preclude firm conclusions, the results of analyses 
of subgroups by Buckland-Wright [41] are consist- 
ent with the hypothesis that JSN accelerates with 
disease severity. 
Consequently, the radiographic inclusion cri- 
teria employed by a DMOAD trial (e.g., to require 
that subjects have, e.g., at least 2mm of 
tibiofemoral JSW at baseline) and the recruitment 
strategy (i.e., from clinic and/or community 
sources) dictated by sample size requirements 
should be taken into account when developing an 
expectation for the overall rate of JSN in the 
placebo group. Furthermore, these data suggest 
that randomization of participants to treatment 
groups should be stratified by recruitment source 
to balance the effect of possibly differing base rates 
of JSN. 
As noted above, the variance of JSN over a given 
interval will have two components: error variation 
(which can be minimized by use of mensural 
procedures with superior eproducibility) and true 
biological variation. Measurement error will be 
distributed randomly and will be of a magnitude 
dictated by the reproducibil ity of repeated 
measures [45]. With regard to biological variation, 
there is no question that in most patients, joint 
damage is ultimately progressive. In sufficient 
time, the disease will progress; and mean joint 
space will diminish (i.e., cumulative JSN will 
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increase) in the vast majority of patients. On 
theoretical grounds, therefore, one might hypoth- 
esize that the longer the period of observation, the 
smaller the variabil ity of JSN will be in relation to 
the mean. 
Indeed, among the studies presented in Table II, 
the two of shortest duration (i.e., l-year) [31, 43] 
estimated the S.D. of JSN to be 200-1000% of the 
mean. In contrast, in four of five studies of longer 
duration (i.e., > 3 years) [33, 39, 42, 44], the S.D. was 
similar to, or even smaller than, the mean value for 
JSN (i.e., + 30%). This apparent inverse relation- 
ship between the duration of observation and ratio 
of S.D. to mean JSN suggests that, given sufficient 
time, true JSN will become sufficiently great as to 
overshadow measurement error and biological 
variability. 
However, pragmatic onsiderations will require 
that DMOAD studies be as short as possible. Time 
is money, and, the longer the study the greater the 
problems with subject retention are likely to be. 
Therefore, any clue as to how to shorten the time 
required for reduction of the within-group variabil- 
ity in JSN in relation to the magnitude of mean 
JSN (and between-groups difference in mean JSN) 
is worth noting. In the only study in Table II to 
employ computerized measurement of JSW from 
digitized (albeit macro-) radiographic mages of OA 
knees in standardized semiflexed position [41], the 
S.D. of JSN (0.268 mm) was comparable with the 
mean cumulative JSN (0.275 mm) after only 18 
months of observation (J. C. Buckland-Wright, 
personal communication). Although, again, a 
caveat must be offered because of the small number 
of observations on which these parameters are 
estimated. This study, nevertheless, i l lustrates the 
potential benefit of increased precision in measure- 
ment of radiographic outcomes in a DMOAD trial. 
biological variation among subjects and the 
variation associated with measurement error. As 
demonstrated by Bloch [45], a decrease in 
measurement error relative to biological variation 
will directly reduce the error term used in the 
statistical analysis of the outcome variable and 
will increase the power of the trial accordingly. 
In comparison with JSW, the variance of JSN 
and its relationship to SEre is more complicated, 
because JSN is the numerical difference between 
two measurements of JSW--both of which will 
contain measurement error. As with JSW, impreci- 
sion of measurement inflates the error term 
directly for statistical tests of JSN. Moreover, 
measurement error reduces the correlation be- 
tween repeated estimates of JSW, further increas- 
ing unaccountable within-group variation in JSN. 
To i l lustrate the effect of measurement precision 
on power, we have performed sample size calcu- 
lations for a hypothetical DMOAD trial using 
respective SEm estimates appropriate for manual 
measurement of JSW in conventional extended 
view radiographs and for computerized, magnifi- 
cation-corrected measurement of JSW in 
semiflexed views of normal and OA knees [25]. In 
this i l lustration, we have assumed a conservative 
annual rate of JSN (0.20 mm/year), study duration 
of 2 years, and a value for the S.D. of JSN equal to 
100% of the mean JSN in the placebo group (i.e., 
0.40 ram). To simplify this exercise, we have used a 
single value (0.80) for the correlation between the 
baseIine and end-of-trial estimates of JSW 
measured without error. Sample size estimates 
were obtained using PC-Size software [46]. 
The remarkable potential for improved measure- 
ment precision to increase the power of a 
placebo-controlled DMOAD trial to detect, e.g., a 
30% reduction of the rate of JSN is shown in Fig. 1. 
Impl icat ions  for the des ign of  a DMOAD tr ial  
EFFECT OF MEASUREMENT PRECIS ION ON SAMPLE 
S IZE  
Because the SEre (i.e., the S.D. of repeated 
measurements) for any outcome variable in a 
clinical trial is a component of within-group 
variabil ity (i.e., the 'error term' used in statistical 
tests of study hypotheses), the precision of 
mesurement can have a large impact on the power 
to detect a significant DMOAD effect. If the 
outcome at the end of the trial were a single 
estimate of JSW, rather than the magnitude of 
JSN, the effect of radiographic or mensural 
imprecision could be readily calculated. Power 
calculations for JSW would be based upon its 
variance, which is the sum of two components: the 
300 
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Normal knees OA knees 
FIG. 1. The effect of measurement precision on sample 
size in a DMOAD trial designed to detect a 30% drug 
effect in which the rate of JSN is 0.2 mm/year in the 
placebo group. (@) Extended view, manual measure- 
ment; ([3) semiflexed view, automated measurement. 
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Compared with a trial in which JSW is measured 
manually in conventional extended views of 
radiographically normal knees, computerized 
measurement would reduce the sample size needed 
to achieve 80% power from 280 to 97 participants/ 
group. For knees with established OA, in which 
computerized measurement is less precise than in 
normals, the required sample size would decrease 
to a lesser extent (i.e., from 267 to 149 participants/ 
group). Nevertheless, a proportional (44%) re- 
duction in recruitment, screening and 
post-randomization costs would be substantial. 
We emphasize that this exercise is intended for 
illustrative purposes and that these sample size 
estimates are not meant o be used in the planning 
of DMOAD trials. Actual sample size calculations 
will be very sensitive to many study-specific 
parameters, including characteristics of the target 
population, sampling strategy, radiographic 
methods, outcome variables and anticipated effect 
size. 
EFFECT OF THE RATE OF JSN ON SAMPLE SIZE AND 
STUDY DURATION 
The same caveats apply to the following 
il lustration of the effect of the rate of JSN on the 
design of a DMOAD trial. Fig. 2 i l lustrates the 
large effect (and the potential for underpowering a 
DMOAD trial) that small differences in assump- 
tion about the rate of JSN in the placebo group 
would have on the size and duration of a 
hypothetical trial designed to detect a 30% 
reduction in the rate of JSN. For the sake of this 
il lustration, we have taken a range of rates of JSN 
in the placebo group (0.10 0.25 mm/year) from the 
low end of the spectrum presented in Table II. The 
i l lustration also presumes that the SD of JSN is 
0.35mm after 24 months (i.e., 70-175% of the 
expected mean JSN in the placebo group across the 
range of annual rates). 
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FIG. 2. The effect of the rate of JSN in the placebo group 
on sample size and duration of a DMOAD trial designed 
to detect a 30% drug effect (E3) sample size; ( I )  
duration. 
In a 24-month DMOAD trial, if the rate of JSN 
in the placebo group were 0.25mm/year and 
treatment with the drug reduced the rate by 30%'; 
87 participants would be required to complete the 
trial in both the treatment group and placebo-con- 
trol groups to have 80% power to detect a 
statistically significant (P<0.05)  drug effect. 
However, for every decrease of 0.025 mm/year in 
the base rate of JSN on the placebo group, sample 
size requirements grow 23-56%. At the extreme, if 
the mean rate of JSN were 0.10mm/year, the 
required sample size would be 535 participants/ 
group sixfold greater than if the rate of JSN were 
0.25mm/year. These sample size estimates are 
about 25% larger than those offered recently by 
Buckland-Wright [16] for a trial of similar 
duration, power, and assumed rate of JSN in the 
placebo group. The reason for this discrepancy is
that our assumed S.D. for ~SN is larger, in absolute 
terms and in relation to the mean, than the value 
of 0.245 mm used by Buckl~nd-Wright [16]. 
Alternatively, if the effect of the annual rate of 
JSN on study duration, rather than on sample size, 
is considered, Fig. 2 i l lustrated that in a trial with 
200 knees/group, if the overall rate of JSN in the 
placebo group is 0.25 mm/year, a30% drug effect 
should be detectable with 80% ~ower  after 16 
months of treatment. If the size of the sample is 
kept constant, each successive 0.025mm/year 
reduction in JSN in the placebo group would 
extend the minimum length of the trial by 2-8 
months. For a rate of JSN of only 0.1 m/year in the 
placebo group, the projected uration of the trial 
would rise to 40 months. 
Conc lus ion  
Is conventional radiography suitable for evalu- 
ation of a DMOAD in patients with knee OA? 
Based 6n our knowledge of (1) the reproducibil ity 
of measurement of JSW, (2) the nature and rate of 
OA progression i  potential target populations for 
a DMOAD trial and (3) the pragmatics and costs of 
clinical trials, it is apparent hat conventional 
radiographic technique, in concert with manual 
measurement of JSW, cannot be endorsed as 
methods for quantitating primary outcomes in 
DMOAD trials. Failure to standardize crucial 
elements of radioanatomic positioning and to auto- 
mate measurement of JSW has been shown to in- 
troduce significant and probably insurmountable 
error variation to estimates of JSW [24, 25]. The 
lack of standardization with respect to radio- 
graphic methods in previous studies of OA 
progression are, in all likelihood, chiefly respon- 
sible for the highly-variable stimates of popu- 
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lat ion parameters  (i.e., mean and var iance of JSW) 
and the rate of O A progression that  these studies 
offer [31, 33, 39-44]. 
Descr ipt ions of h ighly-standardized protocols 
for knee rad iography [16, 25] and for measurement  
of JSW [33, 38] are avai lable. We have i l lustrated 
how the level of precis ion achievable with 
f luoroscopical ly assisted flexion of the knee and 
rotat ion  of the foot, with computerized, magnifi- 
cat ion-corrected measurement  of JSW can, in 
theory,  decrease the sample size required to detect  
a DMOAD effect. Quant i ta t ion  of JSW notwith- 
standing, a h igher  s tandard of reproducib i l i ty  of 
rad ioanatomic  posit ioning in knee rad iography 
also will increase our sensit iv ity to detect pro- 
gression of bony features of OA (e.g., osteophytes).  
We also have presented l imited, but encourag- 
ing, data suggesting that  the level of precis ion 
achievable today can reduce to 18 months the t ime 
required before power calculat ions for hypothesis  
test ing can be predicated on the assumption that  
within-group var iabi l i ty  of JSN is near  the mean of 
JSN in the placebo group. In contrast,  among 
studies using convent iona l  rad iography and man- 
ual measurement,  he min imum interval  required 
for this level of stat ist ical  power may be twice as 
long. 
The precision associated with this level of 
standardizat ion comes at a cost: special t ra in ing of 
technologists in rad ioanatomic  posit ioning of the 
subject (and assurance that  the technologists 
mainta in  the acquired skills), use of f luoroscopy 
and image digit ization, computer  software and 
hardware.  Nevertheless,  if addit ional  studies 
establ ish high inter-technologist  reproducib i l i ty  of 
rad ioanatomic  posit ioning of the knee- -a  neces- 
sity for a mult icenter  t r ia l - -a  powerful  argument  
can be made for the use of this system in future 
DMOAD studies. 
Finally, the design of an eff icient DMOAD tr ial  
would be assisted by the identi f icat ion of inclusion 
cr i ter ia that  would increase the l ikelihood, if not 
the rate, of OA progression among randomized 
part ic ipants.  Considerable interests exists, there- 
fore, in biochemical  and immunochemical  nalyses 
of synovial  fluid or serum [47] and in imaging 
procedures [48] which may identify individuals 
who are at greater  isk for the progression of OA 
than others. To permit  accurate evaluat ion of 
reports of the use of such surrogates,  if radio- 
graphy is used to determine the progression of OA, 
it is important  that  detai led informat ion is 
provided concerning the mensural  .procedures 
employed and their  precision. In the absence of 
such information, considerable risk exists that  the 
potent ia l  use of such surrogates may be misjudged. 
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